POCT Segment Will Grow Faster Than Laboratory Test Market

Kalorama (New York, NY, USA), the healthcare market research publisher, forecasts that the nearly USD17 billion point-of-care test (POCT) market will see faster revenue growth in 2013 than tests sent to central laboratories for processing. This finding was made in a report authored by Sannes & Associates.

In the United States, diabetes and the Affordable Care Act should increase the demand for healthcare services. The legislation accompanying the Affordable Care Act emphasizes preventative services and screening, which should boost POC efforts.

EU governments consider that decentralized testing could control the cost of delivering healthcare to their aging populations. They started placing greater emphasis on the prediction and prevention of disease through more proactive diagnostics. Therefore, the POC testing market in Europe is expected to increase the number of tests available, and the number of test locations.

Japan has highly centralized healthcare delivery that does not leave much room for POC testing in the physician's office. But, Japan's hospitals are increasing their uptake of rapid tests for emergency and critical care use. Japan is the single largest market for rapid flu tests because Roche's Tamiflu is prescribed for all diagnosed cases of influenza

The POC market is growing more rapidly in emerging markets such as China, India, Latin America, Eastern Europe, Russia, and parts of Asia and Africa. Companies entering these markets from regions such as the United States and Europe are now facing competition from local companies emerging in these rapidly growing POC markets.

Kalorama sees growth at 1% faster than the in vitro diagnostics (IVD) market overall due to these factors and others. Roche, Lifescan, Alere, Bayer, and Abbott today dominate POC, but there are many other companies and new entrants. Kalorama identifies and profiles more than 140 of these POC companies in the report.

Related Links:
Kalorama